for expression and local delivery of therapeutics at disease sites
including the intestine, the mouth and the nasopharynx.
ActoBio Therapeutics™ CEO Pieter Rottiers will be presenting at SynBioBeta in San Francisco. Don't miss his overview of the innovative ActoBiotics® platform and its applications on Tuesday October 1 at 4pm.
ActoBio Therapeutics™ has a rich pipeline of therapeutic agents, called ActoBiotics®, that are developed to treat a number of diseases, focusing primarily on disease areas with high unmet needs in immunotherapy, allergy and immune tolerance induction.
ActoBiotics® are based on the well-characterized, safe food-grade bacterium Lactococcus lactis. They are specifically designed and engineered to perform very specific biological interventions across broad therapeutic applications.